[1]张佩彦,秦肖含,王玉珍.肌少症与肝硬化的研究进展[J].肠外与肠内营养杂志,2022,(01):57-61，64.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
　ZHANG Pei-yan,QIN Xiao-han,WANG Yu-zhen.Research progress of sarcopenia in patients with cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2022,(01):57-61，64.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
点击复制

肌少症与肝硬化的研究进展
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2022年01期
页码:
57-61，64
栏目:
综述
出版日期:
2022-01-10

文章信息/Info

Title:
Research progress of sarcopenia in patients with cirrhosis
作者:
张佩彦1; 秦肖含1; 王玉珍2
1.华北理工大学研究生院，河北唐山 063000；2.河北省人民医院消化内科，河北石家庄 050000
Author(s):
ZHANG Pei-yan1;  QIN Xiao-han1;  WANG Yu-zhen2
1. Department of graduate academy, North China University of Science and Technology , Tangshan 063000, Hebei, China；2. Department of Geriatric Gastroenterology, Hebei General Hospital,Shijiazhuang 050000, Hebei, China
关键词:
肌少症 ; 肝硬化 ; 营养代谢
Keywords:
Sarcopenia;  Cirrhosis;  Nutrition metabolism
分类号:
R575.2
DOI:
DOI : 10.16151/j.1007-810x.2022.01.011
文献标志码:
A
摘要:
肌少症是肝硬化的一种常见合并症，发病率为 20% ~ 70%。肌少症暂无诊断金标准，CT为常用的诊断方法。肝硬化发生肌少症的机制是多样的，尽早对合并肌少症者进行干预可改善预后。本文将从肌少症特点、诊断方法、发病机制、治疗与干预方面详细阐述，以期为后续研究提供借鉴。
Abstract:
Sarcopenia is highly prevalent in cirrhosis, with the reported prevalence rate ranging between 20% and 70%. There is no gold standard for the diagnosis of sarcopenia while CT is a common method. The mechanisms of sarcopenia in liver cirrhosis are diverse. Early interventions can improve the prognosis of cirrhosis with sarcopenia. This review summarizes the characteristics, diagnosis methods, mechanisms, treatments and intervention of sarcopenia which aimed to provide a reference for further studies.

参考文献/References:


[1] Ponziani FR, Gasbarrini A. Sarcopenia in Patients with Advanced Liver Disease. Curr Protein Pept Sci, 2018, 19(7): 681-691.
[2] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing, 2010, 39(4): 412-423.
[3] Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 2020, 21(3): 300-307.
[4] Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res, 2016, 46(8): 743-751.
[5] Cheng TY, Lee PC, Chen YT, et al. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinomaafter sorafenib failure. Sci Rep, 2020, 10(1): 18375.
[6] Gu DH, Kim MY, Seo YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol, 2018, 24(3): 319-330.
[7] Locke JE, Shelton BA, Olthoff KM, et al. Quantifying Sex-Based Disparities in Liver Allocation. JAMA Surg, 2020, 155(7): e201129.
[8] Ruiz-Margáin A, Xie JJ, Román-Calleja BM, et al. Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis With or Without Ascites. Clin Gastroenterol Hepatol, 2021, 19(9): 1941-1949.
[9] Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol, 2013, 31 (12): 1539-1547.
[10] Wells CI, McCall JL, Plank LD. Relationship Between Total Body Protein and Cross-Sectional Skeletal Muscle Area in Liver Cirrhosis Is Influenced by Overhydration. Liver Transpl, 2019, 25(1): 45-55.
[11] Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol, 2008, 9(7): 629-635.
[12] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol, 2019, 70(1): 172-193.
[13] Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1948-1958.
[14] Paternostro R, Lampichler K, Bardach C, et al. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver Int, 2019, 39(12): 2374-2385.
[15] Taguchi S, Akamatsu N, Nakagawa T, et al. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma. Clin Genitourin Cancer, 2016, 14(3): 237-243.
[16] Durand F, Buyse S, Francoz C, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol, 2014, 60(6): 1151-1157.
[17] Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and metaanalysis. PloS one, 2017, 12(10): e0186990.
[18] 吴 丹, 陈强谱 . 慢性阻塞性肺疾病相关肌少症的诊断与治疗 . 肠外与肠内营养, 2021, 28(5): 308-312.
[19] Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol, 2012, 10(2):117-125.
[20] Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr, 2019, 38(2): 485-521.
[21] Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest, 1999, 103(3): 365-372.
[22] Tessari P, Kiwanuka E, Vettore M, et al. Phenylalanine and tyrosine kinetics in compensated liver cirrhosis: effects of meal ingestion. Am J Physiol Gastrointest Liver Physiol, 2008, 295(3):G598-604.
[23] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol, 2016, 65(6): 1232-1244.
[24] Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis, 2012, 16(1): 95-131.
[25] Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov, 2015, 14(1): 58-74.
[26] Tandon P, Montano-Loza AJ, Lai JC, et al. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol, 2021, 75 Suppl 1: S147- S162.
[27] Holecek M. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathytherapeutic perspectives. Metab Brain Dis, 2014, 29(1): 9-17.
[28] Welch N, Dasarathy J, Runkana A, et al. Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. Liver Int, 2020, 40(5): 1178-1188.
[29] Qiu J, Thapaliya S, Runkana A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF- κB-mediated mechanism. Proc Natl Acad Sci USA, 2013, 110(45): 18162-18167.
[30] M?ller S, Becker U, Gr?nbaek M, et al. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. J Hepatol, 1994, 21(5): 710-717.
[31] Sinclair M, Gow PJ, Grossmann M, et al. Review article:sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther, 2016, 43(7):765-777.
[32] Keller CW, Fokken C, Turville SG, et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem, 2011, 286(5): 3970-3980.
[33] Paternostro R, Bardach C, Hofer BS, et al. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver Int, 2021, 41(4): 799-809.
[34] van Vugt JLA, Alferink LJM, Buettner S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol, 2018, 68(4): 707-714.
[35] Praktiknjo M, Clees C, Pigliacelli A, et al. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. Clin Transl Gastroenterol,2019, 10(4): e00025.
[36] Artru F, Miquet X, Azahaf M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance. Aliment Pharmacol Ther, 2020, 52(9): 1516-1526.
[37] Praktiknjo M, Book M, Luetkens J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology,2018, 67(3): 1014-1026.
[38] Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int, 2018, 12(4): 377-386.
[39] Lucidi C, Lattanzi B, Di Gregorio V, et al. A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. Liver Int, 2018, 38(5): 851-857.
[40] Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. Transplantation, 2020, 104(7): e188-e198.
[41] Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition, 2015, 31(1): 193-199.
[42] Reuter B, Shaw J, Hanson J, et al. Nutritional Assessment in Inpatients With Cirrhosis Can Be Improved After Training and Is Associated With Lower Readmissions. Liver Transpl, 2019, 25(12): 1790-1799.
[43] 中华医学会肝病学分会, 中华医学会消化病学分会 . 终末期肝病临床营养指南 . 中华肝脏病杂志, 2019, 27(5): 330-342.
[44] 肖慧娟, 韩 涛 . 肝硬化患者营养不良、肌肉减少症及骨质疏松的防治 . 临床肝胆病杂志, 2021, 37(01): 26-30.
[45] Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. Expert Rev Gastroenterol Hepatol, 2018, 12(12): 1229-1244.

相似文献/References:

[1]房 良,荆 雪,田字彬.肌肉减少症与肝硬化的临床研究进展[J].肠外与肠内营养杂志,2018,(05):308.[doi:10.16151/j.1007-810x.2018.05.013]
　FANG Liang,JING Xue,TIAN Zi-bin.A review of the relationship between sarcopenia and cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2018,(01):308.[doi:10.16151/j.1007-810x.2018.05.013]
[2]张 珊,张 伟,李秀华,等.合生素补充联合生活方式干预对非酒精性脂肪肝病人肝硬化和 免疫相关指标的影响[J].肠外与肠内营养杂志,2019,(05):286.[doi:DOI : 10.16151/j.1007-810x.2019.05.007]
　ZHANG Shan,ZHANG Wei,LI Xiu-hua,et al.Effect of synbiotic supplementary combined with lifestyle intervention on liver cirrhosis and immune related indexes in nonalcoholic fatty liver disease[J].PARENTERAL & ENTERAL NUTRITION,2019,(01):286.[doi:DOI : 10.16151/j.1007-810x.2019.05.007]
[3]青 青,袁丹凤,谢 玥,等.肝硬化食管胃曲张静脉内镜治疗术后饮食策略 与预后的关系:系统评价[J].肠外与肠内营养杂志,2020,(02):84.[doi:10.16151/j.1007-810x.2020.02.005]
　QING Qing,YUAN Dan-feng,XIE Yue,et al.Dietary strategies and the relationships with prognosis after endoscopic treatments of gastroesophageal varices in patients with cirrhosis: a systematic review[J].PARENTERAL & ENTERAL NUTRITION,2020,(01):84.[doi:10.16151/j.1007-810x.2020.02.005]
[4]吴 丹,陈强谱.慢性阻塞性肺疾病相关肌少症的诊断与治疗[J].肠外与肠内营养杂志,2021,(05):308.[doi:10.16151/j.1007-810x.2021.05.010]
　WU Dan,CHEN Qiang-pu.Diagnosis and treatment of chronic obstructive pulmonary disease-related sarcopenia[J].PARENTERAL & ENTERAL NUTRITION,2021,(01):308.[doi:10.16151/j.1007-810x.2021.05.010]
[5]严 玮,叶向红,王 敏,等.1例创伤后多发肠瘘、腹壁缺损并肌少症病儿的治疗与护理[J].肠外与肠内营养杂志,2021,(05):317.[doi:10.16151/j.1007-810x.2021.05.012]
[6]陈新宇,周军良,李婷婷,等.相位角与老年肌少症的关系研究[J].肠外与肠内营养杂志,2021,(05):275.[doi:10.16151/j.1007-810x.2021.05.004]
　CHEN Xin-yu,ZHOU Jun-liang,LI Ting-ting,et al.Association of phase angle with sarcopenia in elderly adults[J].PARENTERAL & ENTERAL NUTRITION,2021,(01):275.[doi:10.16151/j.1007-810x.2021.05.004]
[7]韩 雨,杨 洋,叶向红,等.老年恶性肿瘤病人衰弱与肌少症关系的研究进展[J].肠外与肠内营养杂志,2022,(04):248.[doi:10.16151/j.1007-810x.2022.04.010]
　HAN Yu,YANG Yang,YE Xiang-hong,et al.Research progress on the relationship between frailty and sarcopenia in elderly patients with malignant tumors[J].PARENTERAL & ENTERAL NUTRITION,2022,(01):248.[doi:10.16151/j.1007-810x.2022.04.010]
[8]沈 雷,王俊杰,韩 军,等.胃癌病人术前甲状腺激素水平与肌少症的相关性研究[J].肠外与肠内营养杂志,2022,(05):257.[doi:10.16151/j.1007-810x.2022.05.001]
　SHEN Lei,WANG Jun-jie,HAN Jun,et al.Association of thyroid function with sarcopenia in patients with gastric cancer[J].PARENTERAL & ENTERAL NUTRITION,2022,(01):257.[doi:10.16151/j.1007-810x.2022.05.001]
[9]马翠翠,宋 洁,娄婷婷,等.有营养风险的肝硬化病人血清瘦素与脂联素变化及其预测营养风险的可行性[J].肠外与肠内营养杂志,2023,(03):148.[doi:10.16151/j.1007-810x.2023.03.005]
　MA Cui-cui,SONG Jie,LOU Ting-ting,et al.Changes of serum leptin and adiponectin in patients with cirrhosis at nutritional risk and the feasibility of predicting nutritional risk[J].PARENTERAL & ENTERAL NUTRITION,2023,(01):148.[doi:10.16151/j.1007-810x.2023.03.005]

备注/Memo

备注/Memo:
作者简介 ：张佩彦，医师，医学硕士，主要从事消化肝硬化方面的临床研究。E-mail：931803982@qq.com 通讯作者 ：王玉珍，E-mail：wangyuzhen5423@126.com
更新日期/Last Update: 1900-01-01